



## Complete Genome Sequence of an ON1 Human Respiratory Syncytial Virus Strain Isolated in Lebanon in 2015

Amani Ezzeddine,<sup>a,b</sup> Nadia Soudani,<sup>a,b</sup> Chun Kiat Lee,<sup>c</sup> Ghassan Dbaibo,<sup>d,e</sup> Husni Elbahesh,<sup>f</sup> <sup>©</sup> Hassan Zaraket<sup>a,b</sup>

<sup>a</sup>Department of Experimental Pathology, Immunology and Microbiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon

<sup>b</sup>Center for Infectious Diseases Research, Faculty of Medicine, American University of Beirut, Beirut, Lebanon

<sup>c</sup>Department of Laboratory Medicine, National University Health System, Singapore

<sup>d</sup>Department of Pediatrics and Adolescent Medicine, Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon

<sup>e</sup>Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon

fDepartment of Microbiology, Immunology and Biochemistry, University of Tennessee Health Science Center, Memphis, Tennessee, USA

**ABSTRACT** We report here the complete genome sequence of a human respiratory syncytial virus (HRSV) strain obtained from an infant who presented to the emergency room with an acute respiratory illness during the 2014/2015 HRSV season in Lebanon. Analysis revealed that this virus belongs to the ON1 genotype that has recently emerged worldwide.

Luman respiratory syncytial virus (HRSV) is a major cause of acute lower respiratory infections (ALRIs) in children worldwide. The clinical outcomes vary from mild respiratory tract infections to severe bronchiolitis and pneumonia (1). Annually, more than 30 million episodes of HRSV-associated ALRIs occur globally in children under 5 years of age (1). Currently, there is no available vaccine against HRSV. Genome-based characterization of HRSV allows for better understanding of its global diversity and provides information for the development of vaccines, antivirals, and diagnostics (2). HRSV is a member of the family *Paraxymoviridae* and subfamily *Pneumovirinae* (3). It is an enveloped virus with a 15-kb negative-sense single-stranded RNA genome that encodes 11 viral proteins (3). HRSVs are divided into two groups (A and B) based on their antigenic variability. Thirteen HRSV-A genotypes and 20 HRSV-B genotypes have been identified on the basis of the G protein diversity (4). HRSV-A infections are more common than HRSV-B infections. This antigenic variability contributes to the repeated infections that occur throughout life (5).

The isolate RSVA/Lebanon/14LJF289/2015 (JF289) was collected in Lebanon from an infant who presented to the emergency room with an acute respiratory illness during the 2014/2015 HRSV season. The patient had no history of palivizumab use. RNA extraction was performed using a Purelink virus RNA/DNA kit followed by first-strand cDNA synthesis with an RSV-specific primer and SuperScript III reverse transcriptase. Purification of the cDNA was performed using Agencourt AMPure XP beads followed by double-stranded DNA synthesis with a Sigma SeqPlex XE kit. The libraries were prepared with a NEBNext fast library prep kit, and ion sphere particles were generated using the Ion OneTouch 2 system. Sequencing was carried out on the Ion Proton sequencer. The obtained sequences were trimmed and assembled using Geneious software, and the gaps were filled by using the primer-walking method and Sanger sequencing.

Received 14 March 2018 Accepted 22 March 2018 Published 19 April 2018

Citation Ezzeddine A, Soudani N, Lee CK, Dbaibo G, Elbahesh H, Zaraket H. 2018. Complete genome sequence of an ON1 human respiratory syncytial virus strain isolated in Lebanon in 2015. Genome Announc 6:e00316-18. https://doi.org/10.1128/genomeA .00316-18.

**Copyright** © 2018 Ezzeddine et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Address correspondence to Husni Elbahesh, helbahes@uthsc.edu, or Hassan Zaraket, hassan.zaraket@aub.edu.lb. The genome of JF289 contains 15,098 nucleotides, including a 3' leader and 5' trailer. The 11 open reading frames (ORFs) encoding viral proteins include two nonstructural proteins (NS1and NS2), a nucleocapsid protein (N), a matrix protein (M), a phosphoprotein (P), an attachment protein (G), a fusion protein (F), a small hydrophobic protein (SH), transcription elongation factors (M2-1 and M2-2), and a large protein (L). The contents of A, U, G, and C were 38.91%, 27.69%, 15.65%, and 17.74%, respectively. BLAST analysis revealed the highest similarity with RSVA/USA/TH\_10323/2013 with 99% identity. JF289 possessed an N276S substitution in the F protein, which has been associated with partial resistance to palivizumab and may lead to further mutations leading to complete resistance (6, 7).

The sequence of the G protein was aligned with other HRSV-A sequences retrieved from GenBank, and a phylogenetic tree was constructed using the neighbor-joining method with MEGA version 6.0. Based on the tree analysis, JF289 belongs to the recently identified ON1 genotype that has emerged globally since 2010. ON1 has a 72-nucleotide duplication within the G protein's second hypervariable region. The increase in frequency of the ON1 genotype worldwide suggests an ability of this genotype to escape host immunity and sustain transmission.

**Accession number(s).** The complete genome of the RSVA/Lebanon/14LJF289/2015 virus was deposited in GenBank under the accession number MG793382.

## **ACKNOWLEDGMENTS**

We express gratitude to the clinical staff who collected the clinical specimens, and we thank Dima Diab for her technical assistance with sequencing. Next-generation sequencing data were generated in the Molecular Resource Center of Excellence at The University of Tennessee Health Science Center (UTHSC) with the assistance of William Taylor and Lorne Rose.

This work was partly supported by UTHSC College of Medicine funds to H.E. and by the Faculty of Medicine, American University of Beirut MPP fund to H.Z.

## REFERENCES

- Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simões EA, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545–1555. https://doi .org/10.1016/S0140-6736(10)60206-1.
- Agoti CN, Otieno JR, Munywoki PK, Mwihuri AG, Cane PA, Nokes DJ, Kellam P, Cotten M. 2015. Local evolutionary patterns of human respiratory syncytial virus derived from whole-genome sequencing. J Virol 89: 3444–3454. https://doi.org/10.1128/JVI.03391-14.
- Anderson LJ, Hierholzer JC, Tsou C, Hendry RM, Fernie BF, Stone Y, McIntosh K. 1985. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis 151:626–633. https://doi .org/10.1093/infdis/151.4.626.
- 4. Gimferrer L, Andrés C, Campins M, Codina MG, Rodrigo JA, Melendo S,

Martin MC, Fuentes F, Saiz MR, Esperalba J, Bruguera A, Vilca LM, Armadans L, Pumarola T, Antón A. 2016. Circulation of a novel human respiratory syncytial virus group B genotype during the 2014–2015 season in Catalonia (Spain). Clin Microbial Infect 22:97.e5–97.e8. https://doi.org/10 .1016/j.cmi.2015.09.013.

- Sullender WM. 2000. Respiratory syncytial virus genetic and antigenic diversity. Clin Microbial Rev 13:1–15. https://doi.org/10.1128/CMR.13.1.1 -15.2000.
- Adams O, Bonzel L, Kovacevic A, Mayatepek E, Hoehn T, Vogel M. 2010. Palivizumab-resistant human respiratory syncytial virus infection in infancy. Clin Infect Dis 51:185–188. https://doi.org/10.1086/653534.
- Bates JT, Keefer CJ, Slaughter JC, Kulp DW, Schief WR, Crowe JE, Jr. 2014. Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in onrate of binding to the fusion protein. Virology 454-455:139–144. https:// doi.org/10.1016/j.virol.2014.02.010.